Severe Clostridium diffi cile infection after liver and kidney transplantation
https://doi.org/10.23873/2074-0506-2019-11-4-320-329
Abstract
Recent statistics have shown increased rates of morbidity and mortality from Clostridium difficile infection worldwide. This problem is mainly typical for surgical patients and is associated with an antibiotic therapy and a prolonged hospital stay. Recipients of solid organs are at a high risk of developing severe forms of C. difficile infection due to immunosupression. Existing recommendations for the treatment of C. difficile infection are based on the severity of the disease and do not consider patients after liver transplantation. The aim of this work is to determine an actual tactics for the diagnosis and treatment of C. difficile in organ recipients in clinical practice.
About the Authors
K. Yu. Kokina
Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
Kseniya Yu. Kokina Senior Researcher, Gastroenterologist, Department of Liver Transplantation and Surgery
61/2 Shchepkin St., Moscow, 129110
Yu. O. Malinovskaya
Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
Yuliya O. Malinovskaya Research Associate, Gastroenterologist, Department of Liver Transplantation and Surgery
61/2 Shchepkin St., Moscow, 129110
A. B. Sidorenko
Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
Aleksey B. Sidorenko Junior Researcher, Surgeon, Department of Liver Transplantation and Surgery
61/2 Shchepkin St., Moscow, 129110
Ya. G. Moisyuk
Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
Yan G. Moisyuk Prof., Dr. Med. Sci., Head of the Department of Transplantology
61/2 Shchepkin St., Moscow, 129110
References
1. Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiolo gy, diagnosis and understandin g transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206–216. PMID: 26956066 https://doi.org/10.1038/nrgastro.2016.25
2. Kurti Z, Lovasz BD, Mandel MD, Csima Z, Golovics PA, Csako BD, et al. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol. 2015;21(21):6728–6735. PMID: 26074711 https://doi.org/10.3748/wjg.v21.i21.6728
3. European Centre for Disease Prevention and Control. Healthcare-associated infections: Сlostridium difficile infections. Annual epidemiological report for 2016. Stockholm, Sweden: ECDC, 2018.
4. Bassetti M, Villa G, Pecori D, Arzese A, Wilcox M. Epidemiology, diagnosis and treatment of Clostridium difficile infection. Expert Rev Anti Infect Ther. 2012;10(12):1405–1423. PMID: 23253319 https://doi.org/10.1586/eri.12.135
5. Ivashkin VT, Yushchuk ND, Mayev IV, Lapina TL, Poluektova YA, Shifrin OS, et al. Diagnostics and treatment of Clostridium difficile-associated disease: Guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5):56–65. (In Russ.). https://doi.org/10.22416/1382-4376-2016-26-5-56-65
6. Goudarzi M, Seyedjavadi SS, Goudarzi H, Mehdizadeh E. Clostridium difficile Infection: epidemiology, pathogenesis, risk factors, and therapeutic options. Scientifica (Cairo). 2014;2014:916826. PMID: 24991448 https://doi.org/10.1155/2014/916826
7. Nikolaeva IV, Shestakova IV, Murtazina GK. Current strategies for diagnosis and treatment of Clostridium difficileinfection (literature review). Acta Biomedica Scientifica. 2018;3(1):34–42. (In Russ.). https://doi.org/10.29413/ABS.2018-3.1.5
8. Huang H, Wu S, Chen R, Xu S, Fang H, Weintraub A, et al. Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China. Anaerobe. 2014;(30):65–69. PMID: 25219941 https://doi.org/10.1016/j.anaerobe.2014.08.015
9. Shaughnessy MK, Micielli RL, DePestel DD, Arndt J, Strachan CL, Welch KB, et al. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2011;32(3):201–206. PMID:21460503 https://doi.org/10.1086/658669
10. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;3(67):742–748. PMID: 22146873 https://doi.org/10.1093/jac/dkr508
11. Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of duration and type of surgical prophylaxis with Antimicrobial-associated adverse events. JAMA Surg. 2019;154(7):590–598. PMID: 31017647 https://doi.org/10.1001/jamasurg.2019.0569
12. Riddle DJ, Dubberke ER. Сlostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant. 2008;13(6):592–600. PMID: 19060548 https://doi.org/10.1097/MOT.0b013e3283186b51
13. Dullal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant Сlostridium difficile: An underappreciated and increasing cause of death and complications. Ann Surg. 2002;235(3):363–372. PMID: 11882758 https://doi.org/10.1097/00000658-200203000-00008
14. Albright JB, Bonatti H, Mendez J, Kramer D, Stauffer J, Hinder R, et al. Early and late onset Сlostridium difficileassociated colitis following liver transplantation. Transpl Int. 2007;20(10):856–866. PMID: 17854444 https://doi.org/10.1111/j.1432-2277.2007.00530.x
15. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumiati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834. PMID: 25714160 https://doi.org/0.1056/NEJMoa1408913
16. Vecchio AL, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol. 2012;28(1):1–9. PMID: 22134217 https://doi.org/10.1097/MOG.0b013e32834bc9a9
17. Dinh A, Le Monnier A, Emery C. Alami S, Torreton É, Duburcq A, et al. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nationwide inception cohort study. Eur J Clin Microbiol Infect Dis. 2019;38(7):1297–1305. PMID: 30941532 https://doi.org/10.1007/s10096-019-03552-9
18. Cao F, Chen CX, Wang M, Liao HR, Wang MX, Hua SZ, et al. Updated metaanalysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018;98(1):4–13. PMID: 28842261 https://doi.org/10.1016/j.jhin.2017.08.017
19. Wijarnpreecha K, Sornprom S, Thongprayoon C, Phatharacharukul P, Cheungpasitporn W. Nasogastric tube and outcomes of Clostridium difficile infection: a systematic review and meta-analysis. J Evid Based Med. 2018;11(1):40–45. PMID: 29322624 https://doi.org/10.1111/jebm.12288
20. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobialassociated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl1):S19–31. PMID: 18177218 https://doi.org/10.1086/521859
21. Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16(5):630–635. PMID: 31217729 https://doi.org/10.7150/ijms.30739
22. Alfa MJ, Kabani A, Lyerly D, Moncrief S, Neville LM, Al-Barrak A, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomia l outbreak of Clostridium difficileassociated diarrhea. J Clin Microbiol. 2000;38(7):2706–2714. PMID: 10878068
23. Sambol SP, Merrigan MM, Lyerly D, Gerding DN, Johnson S. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun. 2000;68(10):5480–5487. PMID: 10992443 https://doi.org/10.1128/iai.68.10.5480-5487.2000
24. Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, et al. Disease-specific Alterations in the enteric virome in inflammatory bowel disease. Cell. 2016;160(3):447–460. PMID: 25619688 https://doi.org/10.1016/j.cell.2015.01.002
25. Gerding DN, Johnson S, Rupnik M, Aktories K. Clostridium difficile binary toxin CDT: Mechanism, epidemiology, and potential clinical importance. Gut Microbes. 2014;5(1):15–17. PMID: 24253566 https://doi.org/10.4161/gmic.26854
26. Osadchuk MA, Svistunov AA. Antibioticassociated diarrhea in clinical practice. Current Pediatrics. 2014;13(1):102–108. (In Russ.). https://doi.org/10.15690/vsp.v13i1.918
27. Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(Suppl4):S63–81. PMID: 27460910 https://doi.org/10.1016/j.cmi.2016.03.010
28. Kozlov RS, Shelygin YuA, Veselov AV, Dekhnich AV, Zubareva NA, Ershova ON, et al. Review of updated clinical practice guidelines of the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) for Clostridium difficile infection in adults and children. Clinical Microbiology and Antimicrobial Chemotherapy. 2018;20(2):76–124.
29. Valiquette L, Pépin J, Do XV, Nault V, Beaulieu AA, Bédard J, et al. Prediction of complicated Clostridium difficile infection by pleural effusion and increased wall thickness on computed tomography. Clin Infect Dis. 2009;49(4):554–560. PMID: 19591596 https://doi.org/10.1086/600879
30. Burkart NE, Kwaan MR, Shepela C, Madoff RD, Wang Y, Rothenberger DA, et al. Indications and relative utility of lower endoscopy in the management of Clostridium difficile infection. Gastroenterol Res Pract. 2011;2011:626582. PMID: 22028704 https://doi.org/10.1155/2011/626582
31. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–994. PMID: 29562266 https://doi.org/10.1093/cid/ciy149
32. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl2):1–26. PMID: 24118601 https://doi.org/10.1111/1469-0691.12418
33. Kumar D, Humar A. (eds.) The AST Handbook of transplant infections. Philadelphia: John Willey & Sons Ltd; 2011.
34. Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, et al. Timely use of probiotics in hospita lized adults prevents Clostridium dif ficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017;152(8):1889–1900. PMID: 28192108 https://doi.org/10.1053/j.gastro.2017.02.003
35. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and metaanalysis. Open Med. 2013;7(2):e56–e67. PMID: 24348885
36. Goldenberg J.Z., Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:CD006095. PMID: 29257353 https://doi.org/10.1002/14651858.CD006095.pub4
37. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254(3):423–427. PMID: 21865943 https://doi.org/10.1097/SLA.0b013e31822ade48
Review
For citations:
Kokina K.Yu., Malinovskaya Yu.O., Sidorenko A.B., Moisyuk Ya.G. Severe Clostridium diffi cile infection after liver and kidney transplantation. Transplantologiya. The Russian Journal of Transplantation. 2019;11(4):320-329. https://doi.org/10.23873/2074-0506-2019-11-4-320-329
Views:
1016
